Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.23USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
60,334
52-wk High
$10.86
52-wk Low
$1.75

Select another date:

Thu, Jan 4 2018

BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned

* ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED

BRIEF-OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln

* ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage:

BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities

* ONCOMED - ‍CHAIRMAN, PRESIDENT, CEO PAUL HASTINGS WILL RESUME CHAIRMAN OF BOARD RESPONSIBILITIES, EFFECTIVE DEC. 4, 2017​

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

BRIEF-OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial

* OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial Source text for Eikon: Further company coverage:

Select another date: